Companies · Biotechnology

Islet Sciences, Inc

RALEIGH · Biotechnology

Diligence memoA one-page analyst read on Islet Sciences, Inc — recommendation, valuation, rhythm, risks.
$8.5M
Total raised · real
4
Rounds
3.2×
Latest step-up
Top 48%
Sector rank · raised
Series A
Latest stage · inferred · Wed Dec 04 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

Islet Sciences, Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.51× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.
Dormant
  • Last raise 12.6 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Islet Sciences, Inc is one of 4291 Biotechnology companies tracked from RALEIGH. By capital raised it ranks mid-pack (ahead of 53% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2012-03-20 Raised $4.2M (real) Modeled valuation $153M (est)$4.2M$153MSeries A2012Seed · 2012-03-20 Raised $1.4M (real) Modeled valuation $62M (est)$1.4M$62MSeed2012Series A · 2013-12-04 Raised $2.2M (real) Modeled valuation $80M (est)$2.2M$80MSeries A2013Series A · 2013-12-04 Raised $695K (real) Modeled valuation $25M (est)$695K$25MSeries A2013Series A · 2013-12-04 Raised $2.2M (real) Modeled valuation $80M (est)$2.2M$80MSeries A2013+$1.4M+$2.2M+$695K+$2.2MCumulative $11M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.2M · 2012
Bridge · Series A-stage$1.4M · 2012smaller follow-on
Series A extension$2.2M · 2013
Series A extension$695K · 2013
Series A extension$2.2M · 2013

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$80.3M
Base estimate est.
$2.4M
Conservative case
$436.9M
Upside case
$10.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $152.6M · 2012-03-202012Seed · modeled $62.3M · 2012-03-20Series A · modeled $80.3M · 2013-12-04Series A · modeled $25.1M · 2013-12-04Series A · modeled $80.3M · 2013-12-042013
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
12.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
5 mo
Avg between rounds
$5.0M/yr
Capital velocity
14.3 yr
On record since
2012
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.2× above median
This company$8.5M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.4× of median
This company$2.2M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.3× above median
This company$80.3M
Sector median$64.2M

Raised more than 53% of sector peers (real $). Modeled value above 54% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #86 of 111.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Dnanexus, Inc. · Series A Raised $31.6M · modeled $542.3M (est)Foresight Biotherapeutics, Inc. · Series A Raised $17.0M · modeled $542.3M (est)AuraSense Therapeutics, LLC · Series A Raised $33.6M · modeled $535.0M (est)Zyomyx Inc · Series A Raised $15.2M · modeled $514.1M (est)Thrasos Innovation Inc. · Series A Raised $14.0M · modeled $506.1M (est)Champions Oncology, Inc. · Series A Raised $36.8M · modeled $506.1M (est)Merganser Biotech, Inc. · Series A Raised $21.1M · modeled $473.5M (est)Progenics Pharmaceuticals Inc · Series A Raised $12.9M · modeled $467.2M (est)GeneWeave Biosciences, Inc. · Series A Raised $36.3M · modeled $441.0M (est)Aeglea BioTherapeutics Holdings, LLC · Series A Raised $15.8M · modeled $387.1M (est)Hydra Biosciences Inc · Series A Raised $10.5M · modeled $379.9M (est)Brainstorm Cell Therapeutics Inc. · Series A Raised $12.3M · modeled $379.6M (est)Islet Sciences, Inc (this company) Raised $8.5M · modeled $80.3M (est)Islet Sciences, Inc
CompanyStageRaised · realValue · estvs peer med.
Dnanexus, Inc.Series A$31.6M$542.3M3.41×
Foresight Biotherapeutics, Inc.Series A$17.0M$542.3M3.41×
AuraSense Therapeutics, LLCSeries A$33.6M$535.0M3.36×
Zyomyx IncSeries A$15.2M$514.1M3.23×
Thrasos Innovation Inc.Series A$14.0M$506.1M3.18×
Champions Oncology, Inc.Series A$36.8M$506.1M3.18×
Merganser Biotech, Inc.Series A$21.1M$473.5M2.98×
Progenics Pharmaceuticals IncSeries A$12.9M$467.2M2.94×
GeneWeave Biosciences, Inc.Series A$36.3M$441.0M2.77×
Aeglea BioTherapeutics Holdings, LLCSeries A$15.8M$387.1M2.43×
Hydra Biosciences IncSeries A$10.5M$379.9M2.39×
Brainstorm Cell Therapeutics Inc.Series A$12.3M$379.6M2.39×
Islet Sciences, Inc this companySeries A$8.5M$80.3M0.51×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.2M2012-03-20$19.2M$152.6M90%
Seed$1.4M2012-03-20$7.0M$62.3M90%
Series A$2.2M2013-12-04$10.1M$80.3M90%
Series A$695K2013-12-04$3.2M$25.1M90%
Series A$2.2M2013-12-04$10.1M$80.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.2M2012-03-20
    • First recorded raise — entered as Series A.
  2. Seed$1.4M2012-03-20
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.0× smaller than the prior — bridge or down round.
  3. Series A$2.2M2013-12-04
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
  4. Series A$695K2013-12-04
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.2× smaller than the prior — bridge or down round.
  5. Series A$2.2M2013-12-04
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.2× larger than the prior — scaling up.
Intelligence
2014 ~Q2
Modeled next raise · ~5mo cadence
$6.7M
Modeled next size est.range $4.3M$10.7M
3.2×
Last step-up
$5.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
James Green8 other2013-12
Michael Luther3 other2013-12
ERIC BARNETT1 other2013-12
JOHN STEEL1 other2012-03
RICHARD EGAN1 other2012-03
WILLIAM WILKISON1 other2013-12
GEORGE TODARO2012-03
JERRY NADLER2012-03
JOEL PERLIN2012-03
JONATHAN LAKEY2013-12
Registry & provenance

Islet Sciences, Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1425919
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Immune Therapeutics, Inc.BiotechnologySeries A$8.5M$63.5Msame sector · same stage
Ocean Biomedical, Inc.BiotechnologySeries A$8.6M$67.5Msame sector · same stage
CohBar, Inc.BiotechnologySeries A$8.7M$77.5Msame sector · same stage
Regen Biologics IncBiotechnologySeries A$8.8M$61.5Msame sector · same stage
Rejuvitas, Inc.BiotechnologySeries A$8.3M$63.5Msame sector · same stage
Phi Therapeutics, Inc.BiotechnologySeries A$8.9M$74.4Msame sector · same stage
BALX Holdings, LLCBiotechnologySeries A$9.0M$72.3Msame sector · same stage
Rapalogix Health, Inc.BiotechnologySeries A$9.1M$61.4Msame sector · same stage
Frequently asked
How much funding has Islet Sciences, Inc raised?
Islet Sciences, Inc has raised approximately $8.5M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Islet Sciences, Inc's estimated valuation?
Provath's modeled valuation for Islet Sciences, Inc is approximately $80.3M (modeled range $2.4M–$436.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Islet Sciences, Inc at?
Islet Sciences, Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Dec 04.
What does Islet Sciences, Inc do and where is it based?
Islet Sciences, Inc operates in the Biotechnology sector, based in RALEIGH.
Explore related

See where Islet Sciences, Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Islet Sciences, Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.